Effect of Renal Disease on Pharmacokinetics

Slides:



Advertisements
Similar presentations
Assesment of renal function in case of near normal creatinine (<1
Advertisements

Selected Clinical Calculations
Kidney Function Tests Contents: Kidney functions Functional units Renal diseases Routine kidney function tests Serum creatinine Creatinine clearance.
1-C: Renal and Hepatic Elimination
DRUG EXCRETION. The process by which drugs or metabolites are irreversibly transferred from internal to external environment through renal or non renal.
Module 2 # 2 Pharmacokinetics absorption of drugs drugs can be given iv, im, sc, orally (po) if given parenterally, they should.
Pharmacotherapy in the Elderly Judy Wong
Kidney Function Tests Rana Hasanato, MD, KSFCB
Kidney Function Tests Contents: Functional units Kidney functions Renal diseases Routine kidney function tests Serum creatinine Creatinine clearance.
Renal Clearance The renal clearance of a substance is the volume of plasma that is completely cleared of the substance by the kidneys per unit time.
Dose Adjustment in Renal and Hepatic Disease
Drug Disposition Porofessor Hanan hager Dr.Abdul latif Mahesar College of medicine King Saud University.
Excretion of Drugs By the end of this lecture, students should be able to Identify main and minor routes of Excretion including renal elimination and biliary.
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 4 Pharmacokinetics.
Quantitative Pharmacokinetics
Kidney Function Tests. Kidney Function Tests Contents: Kidney functions Functional units Renal diseases Routine kidney function tests Serum creatinine.
Renal Physiology and Function Ricki Otten MT(ASCP)SC
Kidney Function Tests.
Renal Excretion of Drugs
Pharmacology Department
Chapter 4 Pharmacokinetics Copyright © 2011 Delmar, Cengage Learning.
PHARMACOKINETICS Part 3.
Drug Dosing in Special Populations
Renal Clearance. Clearance
Clearance Determinations Arthur G. Roberts. Routes of Elimination.
Excretion of Drugs By the end of this lecture, students should be able to Identify main and minor routes of Excretion including renal elimination and biliary.
Renal Physiology and Function Part II Renal Function Tests
Tubular reabsorption.
Renal Clearance. Renal clearance : It is the volume of plasma that is completely cleared of the substance by the kidneys per unit time. Renal clearance.
Dr. Rida Shabbir DPT IPMR KMU 1. Objectives Describe the concept of renal plasma clearance Use the formula for measuring renal clearance Use clearance.
ALTERED PHARMACOKINETICS IN RENAL INSUFFICIENCY ALTERED PHARMACOKINETICS IN RENAL INSUFFICIENCY BY BY SAMUDRALA VIJAY KUMAR SAMUDRALA VIJAY KUMAR M.PHARM(1.
Ann Bugeja, MD FRCPC Integrative Lecture Week 1. You can access and use this PowerPoint presentation for educational purposes only. It is strictly forbidden.
CLINICAL APPLICATION OF UREA MEASUREMENTS METABOLIC ASPECTS OF KIDNEY METABOLISM.
DOSAGE ADJUSTMENT IN RENAL AND HEPATIC DISEASES Course Title : Biopharmaceutics and Pharmacokinetics – II Course Teacher : Zara Sheikh.
Charles Oo / ASCPT March 06 1 Repeated evaluation of the measured urinary creatinine clearance (CrCL), the predicted creatinine clearance based on Cockcroft-Gault.
By : Dr. Roshini Murugupillai
Stephen R. Ash, MD, FACP IU Health Arnett Lafayette, Indiana 2017
The kidneys and formation of urine
Renal Function Tests (RFTs)
Chapter 3 PHARMACOKINETICS “What the body does to the drug” Lei Wang
Pharmacokinetics.
Excretion of drugs.
Kidney Function Testing
Pharmacokinetics: Pediatrics
Chapter 6 EXCRETION OF DRUGS
Kidney Function Tests Dr Rana hasanato
The kidneys and formation of urine
Estimating Glomerular Filtration Rate In Overweight and Obese Malaysian Subjects Nor-Hayati S1, Soehardy Z1, Norella Kong CT1, Rohana AG2, Nor-Azmi K2,
Kidney Function Tests.
Dosing considerations in obese children
Pharmacokinetics: Pediatrics
The MDRD Study.
Clinical Pharmacokinetics
Renal Disease Filtration, glomeruli generate removal ultrafiltrate of the plasma based on size and charge of molecules End products include urea, creatinine,
Pharmacokinetics & Drug Dosing
Renal Pharmacy Group Beginners Lectures 2018
affected by their interaction with protein
Clinical Pharmacokinetics
Pharmacokinetics and Factors of Individual Variation
Non-Protein Nitrogen (NPN) Compounds (Urea, Creatinine & Uric Acid)
Therapeutic Drug Monitoring
Hawler Medical University
Basic Biopharmaceutics
Biopharmaceutics Chapter-6
SIVANAGESWARARAO MEKALA
Clinical Pharmacokinetics
Clinical Pharmacokinetics
Therapeutic Drug Monitoring
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Presentation transcript:

Effect of Renal Disease on Pharmacokinetics Dr Mohammad Issa Saleh

Introduction Most water-soluble drugs are eliminated unchanged to some extent by the kidney. Drug metabolites that were made more water soluble via oxidation or conjugation are typically removed by renal elimination The nephron is the functional unit of the kidney that is responsible for waste product removal from the body and also eliminates drug molecules

Introduction Unbound drug molecules that are relatively small are filtered at the glomerulus. Glomerular filtration is the primary elimination route for many medications Drugs can be actively secreted into the urine, and this process usually takes place in the proximal tubules Tubular secretion is an active process conducted by relatively specific carriers or pumps that move the drug from blood vessels in close proximity to the nephron into the proximal tubule

Introduction Some medications may be reabsorbed from the urine back into the blood by the kidney Reabsorption is usually a passive process and requires a degree of lipid solubility for the drug molecule. Thus, tubular reabsorption is influenced by the pH of the urine, the pKa of the drug molecule, and the resulting extent of molecular ionization Compounds that are not ionized in the urine are more lipid soluble, better able to pass through lipid membranes, and more prone to renal tubular reabsorption

Effect of Renal Disease on Drug Absorption The bioavailability of most drugs that have been studied in renal failure has not been altered. In chronic renal failure, D-xylose, a marker for small intestinal absorptive function: Absorption was slower (0.555 h-1 vs. 1.03 h-1) Less complete (48.6% vs. 69.4%) Bioavailability decreased for furosemide and pindolol in renal failure

Bioavailability in Renal Disease Unchanged Increased Cimetidine Dextropropoxyphene Ciprofloxacin Erythromycin Codeine Propranolol Digoxin Tacrolimus

Effect of Renal Disease on Drug Distribution Binding of acidic drugs (phenytoin, sulfonamides, warfarin, furosemide) is decreased in uremic patients. Displaced from albumin by organic acids that accumulate in uremia. Higher concentration of free drug may alter interpretation of therapeutic range

Effect of Renal Disease on Drug Distribution Presence of edema and ascites may increase volume of distribution of hydrophilic and highly protein bound drugs In nephrotic syndrome (with extensive loss of plasma proteins) the binding of clofibric acid, the active metabolite of clofibrate, decreases. This results in an increased volume of distribution

Effect of Renal Disease on Drug Distribution Volume of distribution (L/kg) Drug Normal ESRD Increased V Furosemide 0.11 0.18 Gentamicin 0.2 0.29 Phenytoin 0.64 1.4 Trimethoprim 1.36 l.83 Decreased V Digoxin 7.3 4.1 Ethambutol 3.7 1.6

Measurement and Estimation of Creatinine Clearance

Introduction Glomerular filtration rate can be determined by administration of special test compounds such as inulin or 125I-iothalamate; this is sometimes done for patients by nephrologists when precise determination of renal function is needed Glomerular filtration rate (GFR) can be estimated using the modified Modification of Diet in Renal Disease (MDRD) equation: GFR (in mL/min / 1.73 m2) = 186×SCr −1.154×Age−0.203×(0.742, if female)×(1.21, if African-American) For example, the estimated GFR for a 53-year-old African-American male with a SCr = 2.7 mg/dL would be computed as follows: GFR = 186 ⋅ (2.7 mg/dL)−1.154 ⋅ (53 y)−0.203 ⋅ 1.21 = 32 mL/min / 1.73 m2

Introduction However, the method recommended by the Food and Drug Administration (FDA) and others to estimate renal function for the purposes of drug dosing is to measure or estimate creatinine clearance (CrCl). Creatinine is a by-product of muscle metabolism that is primarily eliminated by glomerular filtration Because of this property, it is used as a surrogate measurement of glomerular filtration rate Since creatinine is also eliminated by other routes, CrCl does not equal GFR, so the two parameters are not interchangeable.

Equations for body surface area (BSA): Reference: Dubois; Arch Internal Med 1916;17:863

Equation for Ideal Body Weight (IBW): Devine; Drug Intell Clin Pharm 1974;8:650

Estimation of GFR using serum creatinine (Scr) Creatinine is endogenous substance derived from muscle metabolism, small & not bound to plasma proteins, maintains a fairly constant level, and predominantly filtered ~85% (~15% TS) with minimal non-renal elimination. Proportional to muscle mass & body weight Normal 24-hour excretion: 20-25 mg/kg IBW (males) and 15-20mg/kg (females) Creatinine production decreases with age: 2mg/kg/24hrs per decade Several equations have been published to predict GFR using creatinine clearance (Clcr)

Estimation of GFR using Cockcroft-Gault Equation Cockroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41

Estimation of GFR using Cockcroft-Gault Equation Actual body weight (BW) is used in underweight patients (BW < IBW) Ideal body weight (IBW) in patients of normal weight (BW < 1.3*IBW) Adjusted body weight (ABW) is used for overweight, obese, and morbidly obese patients (BW > 1.3*IBW), suggest use Salazar & Corcoran equation Winter MA, Guhr KN, Berg GM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacotherapy 2012;32:604-12.

Estimation of GFR using Cockcroft-Gault Equation Elderly: The Cockcroft & Gault equation tends to over-estimate CLCR in the elderly. Therefore, an empiric "correction" commonly employed is to round up the serum creatinine to 1.0 mg/dL in elderly patients. However, most studies have found this to be an inappropriate practice which under-estimates true ClCr. Very low serum creatinine: Use of a very low serum creatinine (0.5 mg/dL or less) in the C&G equation leads to a falsely elevated ClCr. Therefore, many practitioners designate 0.7 mg/dL as the minimum SCr which should be used in the equation. Rising serum creatinine: If the serum creatinine is rising, it is likely not at steady-state. SCr may require one week to stabilize following a decrease in renal function. Conversely, after renal function improves to normal, the shift of SCr to its new steady-state level occurs rapidly, since the new half life is now quite short. Thus, the probability that SCr may not be at steady-state is much greater when SCr is rising, than when it is falling. Jelliffe's multi step method, which corrects for rising SCr, is more accurate than C&G in patients with unstable renal function.

Estimation of GFR in obese patients (>130% X IBW) using Salazar-Corcoran Equation Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med. 1988 Jun;84(6):1053-60

Estimation of Clcr in Pediatrics Schwartz GJ et al. J Pediatr. 1984;104:849-54 and Pediatrics. 1976;58:259-63.

Patients with unstable renal function: Jelliffe's multi step If serum creatinine values are not stable, but increasing or decreasing in a patient, the Cockcroft-Gault equation cannot be used to estimate creatinine clearance. In this case, an alternate method must be used which was suggested by Jelliffe and Jelliffe Jelliffe RW, Jelliffe SM. Math Biosci. 14:17-24 (June) 1972

Jelliffe Multi-step method Estimate creatinine Volume of distribution (Vcr) Jelliffe RW, Jelliffe SM. Math Biosci. 14:17-24 (June) 1972

Jelliffe Multi-step method Estimate creatinine production Jelliffe RW, Jelliffe SM. Math Biosci. 14:17-24 (June) 1972

Jelliffe Multi-step method Estimate creatinine clearance (ml/min) where Scr1 is the first serum creatinine and Scr2 is the second serum creatinine both in mg/dL, and Δt is the time that expired between the measurement of Scr1 and Scr2 in days When SCr rises, last SCr observation is used instead of average SCr Jelliffe RW, Jelliffe SM. Math Biosci. 14:17-24 (June) 1972

Jelliffe Multi-step method Estimate creatinine clearance (standardized to BSA, ml/min/1.73m2 ) Jelliffe RW, Jelliffe SM. Math Biosci. 14:17-24 (June) 1972

Estimation of GFR using Jelliffe Multi-step method Actual body weight (BW) is used in underweight patients (BW < IBW) Ideal body weight (IBW) in patients of normal weight (BW < 1.3*IBW) Adjusted body weight (ABW) is used for overweight, obese, and morbidly obese patients (BW > 1.3*IBW)

Estimation of GFR by calculating Clcr from 24-hour urine collection Where: Ucr = urine creatinine concentration (mg/dL); Uvol = total urine volume (ml/24 hrs); SCr = serum creatinine (mg/dL)

Estimation of GFR by calculating Clcr from 24-hour urine collection

Example 1 A creatinine clearance is measured in a 75-year-old Caucasian male patient with multiple myeloma to monitor changes in renal function. The serum creatinine, measured at the midpoint of the 24 hour urine collection, was 2.1 mg/dL. Urine creatinine concentration was 50 mg/dL, and urine volume was 1400 mL. Calculate this patient’s creatinine clearance.